A study by Liang et al. [94,95] demonstrated that hypoxia induced by continued sorafenib treatment resulted in sorafenib resistance via HIF-1α/NF-κB activation in HCC EF24, a molecule with structural similarities to curcumin, which could synergistically augment sorafenib’s antitumor effects and help overcome sorafenib resistance by HIF-1α inhibition [96]. Here, HIF1A is linked to hepatocellular carcinoma.